Biorelevant subcutaneous in vitro test predicts the release of human and fast acting insulin formulations

Int J Pharm. 2024 Apr 25:655:123995. doi: 10.1016/j.ijpharm.2024.123995. Epub 2024 Mar 14.

Abstract

The administration of insulins by subcutaneous injection is nowadays widely prevalent. The injection site is located below the dermis and composed of cells and the extracellular matrix formed of a network of macromolecules such as hyaluronic acid and collagen. Following an injection, the insulins from the formulated products are timely released as drug molecules from the injection site into systemic circulation. In this publication, we show the development of an in vitro setup utilizing a hydrogel composed of a special collagen-hyaluronic acid mixture that mimics the extracellular matrix. Another setup was used for differentiation of the commercially available and research insulin formulations by determining the in vitro permeation characteristics with the results that were correlated with the human in vivo data. Significant differentiation was achieved at 90 % confidence level between the permeation curves of insulin glulisine containing formulations (U100 and a concentrated research formulation), while in case of the insulin lispro containing formulations (U100 and U200) the permeation curves showed similarity. These results demonstrated that the in vitro setup may be used as a tool for formulation development and drug candidate profiling as it is able to differentiate or show similarities between the agglomeration states and concentration of the active pharmaceutical ingredients.

Keywords: Collagen; Extracellular matrix; Hyaluronic acid; IVIVC; Insulin; Subcutaneous absorption.

MeSH terms

  • Collagen
  • Humans
  • Hyaluronic Acid*
  • Hypoglycemic Agents
  • Insulin
  • Insulin Lispro
  • Insulins*

Substances

  • Hyaluronic Acid
  • Insulin
  • Insulin Lispro
  • Insulins
  • Collagen
  • Hypoglycemic Agents